- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Undervalued based on future growth
Australian Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Neuren Pharmaceuticals
Market Cap: AU$2.4b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$18.91
7D
-4.0%
1Y
55.0%
Clinuvel Pharmaceuticals
Market Cap: AU$638.1m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$12.71
7D
-0.5%
1Y
6.0%